Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GJB2 | P29033 | 4/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320956 | 1.00 | MAPK1 (0.52) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL23016754 | 0.86 | LGALS8 (0.57) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL19535635 | 0.85 | MAPK1 (0.40) | MAPK1GJB2CETP | |
| SCHEMBL13708836 | 0.82 | LGALS8 (0.64) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL29291459 | 0.82 | MAPK1 (0.57) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL1842874 | 0.81 | LGALS8 (0.47) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL3392883 | 0.81 | LGALS8 (0.47) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL19669024 | 0.81 | GBA1 (0.43) | MAPK1GJB2GBA1TNF | |
| SCHEMBL18352198 | 0.81 | GBA1 (0.43) | MAPK1GJB2GBA1TNF | |
| SCHEMBL20147800 | 0.80 | TK1 (0.38) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | TMPRSS4, ACE, ACE2 | MAPK1 4868/4885GJB2 4068/4885GBA1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.